Beta Cell Function as a Baseline Predictor of Weight Loss After Bariatric Surgery
Copyright © 2021 Borges-Canha, Neves, Mendonça, Silva, Costa, M. Cabral, Guerreiro, Lourenço, Meira, Salazar, Ferreira, Pedro, Barkoudah, Sande, Lau, B. Souto, Preto, Freitas and Carvalho..
Background: Obesity is a multifactorial disease, which is strongly associated to other metabolic disorders. Bariatric surgery is the most effective treatment of morbid obesity. The role of beta cell function in weight loss after bariatric surgery is uncertain.
Aim: To evaluate the association between beta cell function and percentage of total body weight loss (TBWL%) 1, 2, 3, and 4 years after bariatric surgery in patients with morbid obesity.
Methods: Retrospective longitudinal study in patients with morbid obesity followed in our center between January 2010 and July 2018. Patients were excluded if they had diabetes at baseline or missing data on the needed parameters. We evaluated baseline Homeostatic Model Assessment of IR, Homeostatic Model Assessment of β-cell function (HOMA-beta), Quantitative Insulin Sensitivity Check Index, and Matsuda and DeFronzo index, and TBWL% at years 1 to 4. Linear regression models were used to evaluate the association of indexes of insulin resistance with TBWL% (unadjusted and adjusted for age, sex, BMI, and type of surgery).
Results: There were 1,561 patients included in this analysis. HOMA-beta was negatively associated with TBWL% at second, third, and fourth years post-surgery (β = -1.04 [-1.82 to -0.26], p<0.01; β = -1.16 [-2.13 to -0.19], p=0.02; β = -1.29 [-2.64 to 0.06], p=0.061, respectively). This was not observed in the first year post-surgery nor for the other indexes. Glycemia at baseline was positively associated to EWL% at second and third years post-surgery.
Conclusion: β-cell function at baseline seems to be associated to long-term weight loss, explicitly after the first year post bariatric surgery. This might be a helpful predictor of weight loss in clinical practice.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Frontiers in endocrinology - 12(2021) vom: 23., Seite 714173 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Borges-Canha, Marta [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bariatric surgery |
|---|
| Anmerkungen: |
Date Completed 11.02.2022 Date Revised 11.02.2022 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.3389/fendo.2021.714173 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329996851 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329996851 | ||
| 003 | DE-627 | ||
| 005 | 20231225210333.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fendo.2021.714173 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1099.xml |
| 035 | |a (DE-627)NLM329996851 | ||
| 035 | |a (NLM)34456871 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Borges-Canha, Marta |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Beta Cell Function as a Baseline Predictor of Weight Loss After Bariatric Surgery |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.02.2022 | ||
| 500 | |a Date Revised 11.02.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Borges-Canha, Neves, Mendonça, Silva, Costa, M. Cabral, Guerreiro, Lourenço, Meira, Salazar, Ferreira, Pedro, Barkoudah, Sande, Lau, B. Souto, Preto, Freitas and Carvalho. | ||
| 520 | |a Background: Obesity is a multifactorial disease, which is strongly associated to other metabolic disorders. Bariatric surgery is the most effective treatment of morbid obesity. The role of beta cell function in weight loss after bariatric surgery is uncertain | ||
| 520 | |a Aim: To evaluate the association between beta cell function and percentage of total body weight loss (TBWL%) 1, 2, 3, and 4 years after bariatric surgery in patients with morbid obesity | ||
| 520 | |a Methods: Retrospective longitudinal study in patients with morbid obesity followed in our center between January 2010 and July 2018. Patients were excluded if they had diabetes at baseline or missing data on the needed parameters. We evaluated baseline Homeostatic Model Assessment of IR, Homeostatic Model Assessment of β-cell function (HOMA-beta), Quantitative Insulin Sensitivity Check Index, and Matsuda and DeFronzo index, and TBWL% at years 1 to 4. Linear regression models were used to evaluate the association of indexes of insulin resistance with TBWL% (unadjusted and adjusted for age, sex, BMI, and type of surgery) | ||
| 520 | |a Results: There were 1,561 patients included in this analysis. HOMA-beta was negatively associated with TBWL% at second, third, and fourth years post-surgery (β = -1.04 [-1.82 to -0.26], p<0.01; β = -1.16 [-2.13 to -0.19], p=0.02; β = -1.29 [-2.64 to 0.06], p=0.061, respectively). This was not observed in the first year post-surgery nor for the other indexes. Glycemia at baseline was positively associated to EWL% at second and third years post-surgery | ||
| 520 | |a Conclusion: β-cell function at baseline seems to be associated to long-term weight loss, explicitly after the first year post bariatric surgery. This might be a helpful predictor of weight loss in clinical practice | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a bariatric surgery | |
| 650 | 4 | |a beta cell function | |
| 650 | 4 | |a insulin resistance | |
| 650 | 4 | |a morbid obesity | |
| 650 | 4 | |a weight loss | |
| 700 | 1 | |a Neves, João Sérgio |e verfasserin |4 aut | |
| 700 | 1 | |a Mendonça, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Silva, Maria Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Costa, Cláudia |e verfasserin |4 aut | |
| 700 | 1 | |a M Cabral, Pedro |e verfasserin |4 aut | |
| 700 | 1 | |a Guerreiro, Vanessa |e verfasserin |4 aut | |
| 700 | 1 | |a Lourenço, Rita |e verfasserin |4 aut | |
| 700 | 1 | |a Meira, Patrícia |e verfasserin |4 aut | |
| 700 | 1 | |a Salazar, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Ferreira, Maria João |e verfasserin |4 aut | |
| 700 | 1 | |a Pedro, Jorge |e verfasserin |4 aut | |
| 700 | 1 | |a Barkoudah, Ebrahim |e verfasserin |4 aut | |
| 700 | 1 | |a Sande, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Lau, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a B Souto, Selma |e verfasserin |4 aut | |
| 700 | 1 | |a Preto, John |e verfasserin |4 aut | |
| 700 | 1 | |a Freitas, Paula |e verfasserin |4 aut | |
| 700 | 1 | |a Carvalho, Davide |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in endocrinology |d 2010 |g 12(2021) vom: 23., Seite 714173 |w (DE-627)NLM208813357 |x 1664-2392 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2021 |g day:23 |g pages:714173 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fendo.2021.714173 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2021 |b 23 |h 714173 | ||